Evaluation of pain scores during intravitreal injection in systemic conditions and in conjunction with medications
Authors:
Open Access
- 24 August 2025
- journal article
- Published by SAGE Publications in Therapeutic Advances in Ophthalmology
- Vol. 17
Abstract
Background: Intravitreal injection (IVI) is a common practice in today’s ophthalmology clinics. The pain that patients will experience after the application may be important in compliance with the treatment. Objectives: This study aimed to investigate the correlation between various clinical characteristics of patients receiving IVI and corresponding visual analogue scale (VAS) scores (0: no pain to 10: severe pain). Design: Single-centre, Prospective study. Methods: A total of 313 participants (168 females, 145 males) with a mean age of 66.91 ± 9.67 years underwent IVI for diabetic retinopathy (DRP), retinal vein occlusion (RVO), or age-related macular degeneration (AMD). Eye examinations, including visual acuity and intraocular pressure measurements, were also conducted, and injection indications were determined based on dilated fundus examinations and spectral domain optical coherence tomography images. Following the injections, the researchers solicited VAS scores ranging from 0 to 10 (no pain to severe pain). The study explored the relationships between clinical characteristics, headache frequency, joint and muscle pain, analgesic use, surgical history, antidepressant use, vasovagal syncope, previous injections, and VAS score. Results: The mean VAS score was 4.77 ± 2.90. While DRP and RVO had similar VAS scores (4.95 ± 2.98 and 5.22 ± 2.70, respectively), the AMD group had significantly lower scores (4.09 ± 2.64). Compared with nonusers, antidepressant users had significantly greater VAS scores (5.79 ± 3.43) (4.52 ± 2.70) ( p < 0.05). Patients with a history of syncope had significantly greater VAS scores ( p < 0.05). In patients reporting monthly headaches, a positive correlation was found between headache frequency and VAS score ( r = 0.23, p < 0.01). Conclusion: For individuals experiencing daily headaches, inquiries about vasovagal syncope and antidepressant use may be beneficial, considering the potential association of these symptoms with higher VAS scores after IVIs.Keywords
This publication has 27 references indexed in Scilit:
- Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literatureEye, 2013
- Effect of Ketorolac 0.5% Drops on Patients' Pain Perception During Intravitreal Injection ProcedureJournal of Ocular Pharmacology and Therapeutics, 2012
- Evaluation of Pain in Intravitreal Bevacizumab InjectionsCurrent Eye Research, 2012
- FACTORS AFFECTING PATIENTS' PAIN INTENSITY DURING IN OFFICE INTRAVITREAL INJECTION PROCEDURERetina, 2012
- COMPARISON OF TOPICAL ANESTHETICS FOR INTRAVITREAL INJECTIONSRetina, 2012
- RANDOMIZED TRIAL OF ANESTHETIC METHODS FOR INTRAVITREAL INJECTIONSRetina, 2011
- Intravitreal Injection Anesthesia—Comparison of Different Topical Agents: A Prospective Randomized Controlled TrialAmerican Journal of Ophthalmology, 2011
- Complications of intravitreal injectionsCurrent Opinion in Ophthalmology, 2010
- Endophthalmitis: Pathogenesis, clinical presentation, management, and perspectivesClinical Ophthalmology, 2010
- INTRAVITREAL INJECTION OF THERAPEUTIC AGENTSRetina, 2009